There has been no significant differences in HbA1c levels or severe hypoglycaemia events between two organizations, with both organizations achieving a comparable HbA1c reduction relative to baseline. consequential insulin deficiency[1]. Insulin replacement therapy is the mainstay of treatment aiming to reproduce physiological levels of circulating insulin attained by the healthy pancreas. Modern medical management is by multiple daily insulin injections to cover basal insulin and prandial requirements, and insulin pump therapy which delivers insulin by applying pre-programmed basal rates and insulin boluses at meal times permitting greater flexibility[2]. The first externally worn insulin pump products were Ibutamoren mesylate (MK-677) developed in 1977 and shipped insulin subcutaneously[3]. The rationale for implantable pump (IP) therapy was instigated by the need for a far more physiological path of insulin delivery, whilst mitigating body wear issues and gadget burden. The first implantable pump was applied in 1979[4] with the expected progress on the implantable artificial pancreas, which unfortunately failed to materialise. Early decades of IP utilised either intravenous or intraperitoneal routes, depending on the IP model used[5]. However , due to the greater risk of thrombosis and illness observed with all the latter, the intraperitoneal path has prevailed[6]. Although from a physiological standpoint, IP insulin delivery seems to be an attractive option and closer to the normal physiology, its medical application continues to be limited to selected groups of individuals and restricted to specialised medical centres[710]. The technical properties in the IP systems, physiological aspects related to intraperitoneal insulin delivery, clinical proof, limitations and outlook are discussed in this review, with focus on intraperitoneal IP systems. An electronic search of Medline (via Pubmed) and the public register of clinical trials (www.clinicaltrials.org) was conducted. Keywords (implantable pump, intraperitoneal insulin delivery, type 1 diabetes, clinical trials) combined with relevant MeSH terms were used. A secondary search strategy was conducted using these keywords and terms in the summary databases, and the bibliographies of retrieved papers were looked. Additional papers known to the authors were used. == 2 . Technical description and overview of implantable pumps == The 1st generation of commercial intraperitoneal IP systems developed in the 1980s and 1990s included the MIP 2001 pump (Minimed), the Promedos ID1/ID3 pump (Siemens Ibutamoren mesylate (MK-677) AG), and the Model 1000 pump (Infusaid)[5, 6, 11]. The MIP 2007D pump (Medtronic Minimed, Northridge, CA, USA) is currently the only available commercial IP system. Its clinical use is limited to Europe. IP systems are implanted at the reduced quadrants in the abdomen below general anaesthesia[12] (Figure 1). The MIP 2007D pump Rabbit polyclonal to PPP1CB has a diameter of 8cm, thickness of 2cm and contains up to 15ml Ibutamoren mesylate (MK-677) of insulin which is shipped via a catheter placed within the peritoneal cavity. The tip in the catheter is usually directed on the liver. Post-procedure, patients are required to undergo twenty four hours of stringent bedrest, accompanied by wearing a supportive belt to get 4 to 6 weeks. They may be restricted coming from lifting heavy dumbbells and intense physical activity to get 6 weeks post-procedure. Insulin delivery is usually remotely controlled by the user using a pager-sized hand-held device which allows for bolus delivery at mealtime and to correct substantial glucose beliefs with pre-programmed basal infusion rates (Figure 2). The insulin reservoir is refilled transcutaneously through a central insulin refill port at a dedicated outpatient medical center at least every 3 months, depending on individual insulin requirements. The IP device parts are biocompatible.